Central AsianResearch Index

Сравнение эффективности оригинальной и генерической формы клопидогреля у больных с ИБС

Background. To evaluate the antiaggregation activity and clinical tolerability of Areplex (75 mg, ADAMED, Poland) compared to Plavix (75 mg, Sanofi-Winthrop Industrie, France) in CAD patients. Materials and methods. A blinded, randomized, two-parallel-group study included 40 patients with stable angina (FC I-IV). Platelet aggregation was assessed using the AP 2110 analyzer (SOLAR) with ADP (5 µmol/L) and arachidonic acid (0.5 mg/mL) inducers after a 300 mg loading dose. Results. At 24 hours post-dose, both groups showed significant reductions in aggregation degree and rate (p<0.05), with no intergroup differences (p>0.05). Safety profiles were comparable, with no adverse events reported. Conclusion. Areplex demonstrated bioequivalence to Plavix, with good tolerability, supporting its use as an effective antiplatelet agent in CAD patients.

Сведения

Опубликовано
2025 · Т. 2, № 1, С. 4-10
Язык
Русский
ISSN
3060-4850
Издатель
Republican Specialized Scientific-Practical Medical Center of Cardiology